Krystal Biotech, Inc. KRYS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
- Krystal Biotech, Inc. (KRYS) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $2.11M in Q1 2026.
- How has Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
- Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number decreased by 6.9% year-over-year, from $2.26M to $2.11M.
- What is the long-term trend for Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 18.9% compound annual growth rate (CAGR), from $853.61K to $2.03M.